Insights into therapy: Tryptophan oxidation and HIV infection

Science Translational Medicine

Volumn 2, Issue 32, 2010, Pages

  Murray, Michael F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLFORMAMIDASE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG;

CATABOLISM; ENZYME ACTIVITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN INTAKE; REGULATORY T LYMPHOCYTE; SHORT SURVEY; TRYPTOPHAN OXIDATION;

3-HYDROXYANTHRANILIC ACID; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; DENDRITIC CELLS; DISEASE PROGRESSION; ENZYME INHIBITORS; HIV INFECTIONS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-17; KYNURENINE; OXIDATION-REDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN; VIRAL LOAD;

EID: 77952968839     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001082     Document Type: Short Survey

References (30)

1. D. Favre, J. Mold, P. W. Hunt, B. Kanwar, P. Loke, L. Seu, J. D. Barbour, M. M. Lowe, A. Jayawardene, F. Aweeka, Y. Huang, D. C. Douek, J. M. Brenchley, J. N. Martin, F. M. Hecht, S. G. Deeks, J. M. McCune, Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of Th17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2, 32ra36 (2010).
2. H. J. Ball, H. J. Yuasa, C. J. Austin, S. Weiser, N. H. Hunt, Indoleamine 2, 3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 41, 467-471 (2009).
3. A. J. Muller, P. A. Scherle, Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6, 613-625 (2006).
4. K. Schroecksnadel, R. Zangerle, R. Bellmann-Weiler, K. Garimorth, G. Weiss, D. Fuchs, Indoleamine-2, 3-dioxygenase and other interferon-gamma- mediated pathways in patients with human immunodefi ciency virus infection. Curr. Drug Metab. 8, 225-236 (2007).
5. S. K. Schmidt, A. Müller, K. Heseler, C. Woite, K. Spekker, C. R. MacKenzie, W. Däubener, Antimicrobial and immunoregulatory properties of human tryptophan 2, 3-dioxygenase. Eur. J. Immunol. 39, 2755-2764 (2009).
6. T. J. Connor, N. Starr, J. B. O'Sullivan, A. Harkin, Induction of indolamine 2, 3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-gamma? Neurosci. Lett. 441, 29-34 (2008).
7. C. R. MacKenzie, K. Heseler, A. Müller, W. Däubener, Role of indoleamine 2, 3-dioxygenase in antimicrobial defence and immuno-regulation: Tryptophan depletion versus production of toxic kynurenines. Curr. Drug Metab. 8, 237-244 (2007).
8. M. P. Heyes, K. Saito, A. Lackner, C. A. Wiley, C. L. Achim, S. P. Markey, Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirusinfected macaques. FASEB J. 12, 881-896 (1998).
9. R. Yoshida, O. Hayaishi, Induction of pulmonary indoleamine 2, 3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. U.S.A. 75, 3998-4000 (1978).
10. J. M. Brenchley, D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, B. R. Blazar, B. Rodriguez, L. Teixeira-Johnson, A. Landay, J. N. Martin, F. M. Hecht, L. J. Picker, M. M. Lederman, S. G. Deeks, D. C. Douek, Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006).
11. P. Terness, T. M. Bauer, L. Röse, C. Dufter, A. Watzlik, H. Simon, G. Opelz, Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447-457 (2002).
12. T. Hayashi, J. H. Mo, X. Gong, C. Rossetto, A. Jang, L. Beck, G. I. Elliott, I. Kufareva, R. Abagyan, D. H. Broide, J. Lee, E. Raz, 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc. Natl. Acad. Sci. U.S.A. 104, 18619-18624 (2007).
13. D. Favre, S. Lederer, B. Kanwar, Z. M. Ma, S. Proll, Z. Kasakow, J. Mold, L. Swainson, J. D. Barbour, C. R. Baskin, R. Palermo, I. Pandrea, C. J. Miller, M. G. Katze, J. M. McCune, J. Luban, Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5, e1000295 (2009).
14. E. R. Pfefferkorn, M. Eckel, S. Rebhun, Interferon-gamma suppresses the growth of Toxoplasma gondii in human fi broblasts through starvation for tryptophan. Mol. Biochem. Parasitol. 20, 215-224 (1986).
15. A. J. Muller, J. B. DuHadaway, P. S. Donover, E. Sutanto-Ward, G. C. Prendergast, Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312-319 (2005).
16. C. Uyttenhove, L. Pilotte, I. Théate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, B. J. Van den Eynde, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat. Med. 9, 1269-1274 (2003).
17. A. L. Mellor, P. Chandler, G. K. Lee, T. Johnson, D. B. Keskin, J. Lee, D. H. Munn, Indoleamine 2, 3-dioxygenase, immunosuppression and pregnancy. J. Reprod. Immunol. 57, 143-150 (2002).
18. G. Brandacher, R. Margreiter, D. Fuchs, Clinical relevance of indoleamine 2, 3-dioxygenase for alloimmunity and transplantation. Curr. Opin. Organ Transplant. 13, 10-15 (2008).
19. G. J. Guillemin, B. J. Brew, C. E. Noonan, O. Takikawa, K. M. Cullen, Indoleamine 2, 3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 31, 395-404 (2005).
20. M. Platten, P. P. Ho, S. Youssef, P. Fontoura, H. Garren, E. M. Hur, R. Gupta, L. Y. Lee, B. A. Kidd, W. H. Robinson, R. A. Sobel, M. L. Selley, L. Steinman, Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310, 850-855 (2005).
21. C. M. Forrest, G. M. Mackay, N. Stoy, M. Egerton, J. Christofides, T. W. Stone, L. G. Darlington, Tryptophan loading induces oxidative stress. Free Radic. Res. 38, 1167-1171 (2004).
22. S. R. Daniels, J. I. Hudson, R. I. Horwitz, Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome. J. Clin. Epidemiol. 48, 1413-1427, discussion 1429-1440 (1995).
23. Information produced by a search of D-1MT on Clinical-Trials.gov, a Web-based registry of federally and privately supported clinical trials conducted in the United States and around the world: http://clinicaltrials.gov/ (accessed 4 April 2010).
24. A. Boasso, M. Vaccari, D. Fuchs, A. W. Hardy, W. P. Tsai, E. Tryniszewska, G. M. Shearer, G. Franchini, Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. J. Immunol. 182, 4313-4320 (2009).
25. U. F. Röhrig, L. Awad, A. Grosdidier, P. Larrieu, V. Stroobant, D. Colau, V. Cerundolo, A. J. Simpson, P. Vogel, B. J. Van den Eynde, V. Zoete, O. Michielin, Rational design of indoleamine 2, 3-dioxygenase inhibitors. J. Med. Chem. 53, 1172-1189 (2010).
26. A. K. Witkiewicz, C. L. Costantino, R. Metz, A. J. Muller, G. C. Prendergast, C. J. Yeo, J. R. Brody, Genotyping and expression analysis of IDO2 in human pancreatic cancer: A novel, active target. J. Am. Coll. Surg. 208, 781-787, discussion 787-789 (2009).
27. The National Center for Biotechnology Information Single Nucleotide Polymorphism database: http://www.ncbi.nlm.nih.gov/SNP/snp-ref.cgi?locusId= 169355 (accessed 4 April 2010).
28. M. F. Murray, Tryptophan depletion and HIV infection: A metabolic link to pathogenesis. Lancet Infect. Dis. 3, 644-652 (2003).
29. M. F. Murray, M. Langan, R. R. MacGregor, Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. Nutrition 17, 654-656 (2001).
30. M.F.M. is an inventor on U.S. patent 7, 012, 086, "Treatment of retrovirus induced derangements with niacin compounds."